Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -187.80% is 24% below its 5-year average of -151.14%, around the middle of its 5-year range (-268.92%–-72.98%).
11.99% above its 12-month average of -213.40%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -61.47%.
RETURN ON ASSETS (ROA)
-187.80%
RETURN ON ASSETS (ROA) AVG TTM
-213.40%
RETURN ON ASSETS (ROA) AVG 3Y
-188.65%
RETURN ON ASSETS (ROA) AVG 5Y
-151.14%
RETURN ON ASSETS (ROA) AVG 10Y
-153.67%
RETURN ON ASSETS (ROA) AVG 15Y
-121.45%
RETURN ON ASSETS (ROA) AVG 20Y
-117.87%
CURRENT VS TTM AVG
+11.99%
CURRENT VS 3Y AVG
+0.45%
CURRENT VS 5Y AVG
-24.26%
CURRENT VS 10Y AVG
-22.21%
CURRENT VS 15Y AVG
-54.63%
CURRENT VS 20Y AVG
-59.32%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-482.05%
vs the sector median at left
Galectin Therapeutics Inc.
Market Cap
$247.62M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$247.27M
Return on Assets (ROA)
-30.39%
TTM Avg
-25.00%
3Y Avg
-35.54%
5Y Avg
-31.17%
Market Cap
$248.50M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$249.79M
Return on Assets (ROA)
-55.66%
TTM Avg
-26.79%
3Y Avg
-50.07%
5Y Avg
-50.07%
Market Cap
$241.94M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$241.39M
Return on Assets (ROA)
29.16%
TTM Avg
-1.71%
3Y Avg
-34.07%
5Y Avg
-33.80%
Market Cap
$241.34M
Return on Assets (ROA)
-50.89%
TTM Avg
-41.00%
3Y Avg
-37.00%
5Y Avg
-42.85%
Market Cap
$255.88M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$239.02M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $247.62M | -187.80% | -213.40% | -188.65% | -151.14% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | -30.39% | -25.00% | -35.54% | -31.17% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | -114.79% | -67.19% | -63.94% | -45.91% |
| Upstream Bio, Inc. (UPB)vs › | $249.79M | -55.66% | -26.79% | -50.07% | -50.07% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | -14.72% | -16.00% | -18.82% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 29.16% | -1.71% | -34.07% | -33.80% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | -50.89% | -41.00% | -37.00% | -42.85% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -2.06% | -16.77% | -17.09% | -12.28% |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | -38.25% | -20.05% | -26.23% | -29.50% |
| High Tide Inc. (HITI)vs › | $239.01M | -8.99% | -7.90% | -14.69% | -13.78% |
ROA
-187.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -157.87% |
| 2024-12-31 | -268.92% |
| 2023-12-31 | -145.62% |
| 2022-12-31 | -182.18% |
| 2021-12-31 | -72.98% |
| 2020-12-31 | -79.27% |
| 2019-12-31 | -27.43% |
| 2018-12-31 | -154.34% |
| 2017-12-31 | -390.17% |
| 2016-12-31 | -135.71% |
| 2015-12-31 | -75.84% |
| 2014-12-31 | -53.20% |
| 2013-12-31 | -112.83% |
| 2012-12-31 | -101.19% |
| 2011-12-31 | -165.08% |
| 2010-12-31 | -89.35% |
| 2009-12-31 | -1711.47% |
| 2008-12-31 | -447.59% |
| 2007-12-31 | -529.35% |
| 2006-12-31 | -50.18% |
| 2005-12-31 | -131.86% |
| 2004-12-31 | -64.63% |
| 2003-12-31 | -60.90% |
| 2002-12-31 | -161.11% |
| 2001-12-31 | -224.75% |
| 2000-12-31 | -82.61% |
